AAV-Helper Plasmid: AAV9 Production, pNLRep-Cap1-Kan
Gene therapy experts at Nationwide Children’s Hospital have made significant advancements in designing optimal viral vectors for producing Good Manufacturing Practice (GMP)-grade viral vector products. Adeno-associated virus (AAV) serotypes such as AAV1, 2, 2.5, 3, 5, 6, 8, 9 and rh74 have properties optimized by these researchers. The new plasmid named pNLRep-Cap1- Kan has several improvements including modifications
that provide a significant improvement in packaging efficiency of AAV vectors, reduction in
potential to form replication competent AAV and the inclusion of the ampicillin resistance gene. Dr. Scott Loiler and his team have made additional optimized vectors for AAVrh74, and AAV9 that allow for more efficient purification and improved CNS transduction, respectively.
|
|
